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A 28-year-old male was referred to our hospital with dyspnea. He was diagnosed as having chronic
thromboembolic pulmonary hypertension, and a pulmonary endarterectomy (PEA) was performed.
However, exertional dyspnea remained because of residual pulmonary hypertension; therefore, the
patient was re-admitted to our hospital 1 year after PEA. We performed computed tomography and
pulmonary angiography and found web and band lesions in the distal pulmonary artery with a high
pulmonary artery pressure. Although further management was complicated because the patient had an
anaphylactic shock to iodine-based contrast media, we eventually completed ﬁve sessions of balloon
pulmonary angioplasty (BPA) using gadolinium contrast medium. His symptoms and hemodynamics
dramatically improved after a series of BPA. After 15 months, mean pulmonary arterial pressure reduced
from 67 mmHg to 20 mmHg, and subjective symptoms improved from stage Ⅳ to I as per the WHO
classiﬁcation system. BPA is a potential procedure for residual pulmonary hypertension after PEA and
could be safely performed using gadolinium contrast medium for patients with iodine allergy.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
The effectiveness of balloon pulmonary angioplasty (BPA) for
chronic thromboembolic pulmonary hypertension (CTEPH) is
known [1,2]; however, the management of anaphylaxis to contrast
media is rarely reported in this context. Here we report a 28-year-
old man with no history of iodine allergy who presented with re-
fractory CTEPH and developed anaphylaxis to iodine contrast me-
dia during BPA. We describe the case history and use of gadolinium
contrast media for BPA.2. Case presentation
A 28-year-old male had never been diagnosed with an iodine
allergy. At 27 years of age, the patient underwent pulmonaryLtd. This is an open access article uendarterectomy (PEA) for central CTEPH caused by anti-
phospholipid antibody syndrome. At that time, his mean pulmo-
nary arterial pressure (mPAP) was reduced from 56 mmHg to
20mmHg, and his subjective symptoms improved from stage III to I
as per the World Health Organization (WHO) classiﬁcation system.
Warfarin anticoagulation was initiated before performing PEA, and
good control was achieved with a target of a PT-INR of approxi-
mately 2.0e2.5. However, 1 year later, the patient's condition
worsened because of an acute embolism. At this time, he was
classiﬁed as WHO stage II and was subsequently hospitalized for
additional treatment. Blood analysis indicated elevated lupus
anticoagulant and D-dimer levels, along with ﬁndings indicative of
right ventricular failure, including elevated B-type natriuretic
peptide, uric acid, GOT, and GPT levels (Table 1). Chest X-ray
revealed an enlarged pulmonary artery shadow with a cardiotho-
racic ratio of 55% and protrusion of the left second and fourth aortic
arches (Fig. 1). Electrocardiogram revealed right axis deviation; a
pulmonary P wave in leads II, III, and aVF; and a negative T wave in
leads III, aVF, and V1e4 (Fig. 2). Echocardiogram revealednder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Blood sample analysis.
WBC (ml) 7600 GOT (IU/l) 40 BUN (mg/dl) 15
RBC (ml) 510  104 GPT (IU/l) 75 PT-INR 2.05
Hb (g/dl) 17 LDH (IU/l) 308 D-dimer (mg/ml) 3.4
Plt (ml) 24  104 T-bil (mg/dl) 1.9 FDP (mg/ml) 13
Na (mEq/l) 143 UA (mg/dl) 7.6 BNP (pg/ml) 100
K (mEq/l) 3.9 Cre (mg/dl) 1.01 Lupus AC 1.39
WBC: White Blood cell, RBC: Red Blood Cell, Hb: Hemoglobin, Plt: Platelet, Na:
Natrium, K: Kalium, GOT: Glutamic Oxaloacetic Transaminase, GPT: Glutamic Py-
ruvic Transaminase, LDH: Lactate Dehydrogenase, T-bil: Total Bilirubin, UA: Uric
Acid, Cre: Creatinine, BUN: Blood Urea Nitrogen, PT-INR: Prothrombin Time Inter-
national Normalized Ratio, FDP: Fibrin Degradation Products, BNP: Brain Natriuretic
Peptide, LA: Lupus Anticoagulant.
Fig. 1. Chest X-ray Film. Chest X-ray images showing cardiac dilatation with a
cardiothoracic ratio of 55%, enlarged pulmonary shadow and enlargement of the left
second and fourth aortic arches.
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ventricular displacement (Fig. 3). Marked elevation of 95 mmHg
was also noted in the tricuspid regurgitation pressure gradient
(TRPG). We conﬁrmed an exacerbation of pulmonary hypertension
by ﬁnding mPAP of 57 mmHg and a pulmonary vascular resistance
of 12.3 Wood units on cardiac catheterization. Pulmonary capillary
wedge pressure was 6 mmHg, right atrial pressure was 2 mmHg,
and the cardiac index was 2.4 L/min/m2 (Table 2). Pulmonary
arteriography revealed webbing, bands, abrupt narrowing, and
disruption (Fig. 4), and pulmonary ventilation/perfusion scintig-
raphy revealed a mismatch (Fig. 5). The ﬁndings were consistent
with CTEPH.
We suspected that a new pulmonary thromboembolism had
developed and, although we performed thrombolytic therapy withurokinase, the effects were limited. His PT-INR was controlled at
2.5e3.0with warfarin and aspirin administration. However, one
month later, his mPAP reached 67 mmHg, and he developed he-
moptysis. His condition worsened to WHO stage IV, and he lapsed
into a catecholamine-dependent state. Sildenaﬁl (60 mg), 5 mg
ambrisentan, and 180 mg beraprost were used as speciﬁc therapies
to treat pulmonary hypertension, but they had little effect. When
iodine contrast medium was used in an investigation after hospi-
talization, the patient had developed a rash. Therefore, 30 mg
prednisolone, 20 mg famotidine, and 2 mg D-chlorpheniramine
maleate were administered as premedications before contrast-
enhanced computed tomography with iopamidol (Iopamiron 370,
Bayer, Land Nordrhein-Westfalen, Germany). Despite our efforts,
the patient suffered an anaphylactic shock after the test. The CT
images we obtained suggested progression of the pulmonary
arterial lesion. However, the anaphylaxis meant that it was difﬁcult
to perform tests and treatments that relied on iodine-based
contrast agents. Moreover, we had to consider the fact that
within a very short period, the patient's condition had drastically
worsened and he was in a life-threatening state.
At this point, we examined a report describing percutaneous
transluminal coronary angioplasty using gadolinium and digital
subtraction angiography for a patient with unstable angina who
was allergic to iodine and another report that described the use of
percutaneous transluminal angioplasty for a pediatric patient with
pulmonary stenosis [3,4]. It was determined that there was a high
risk that repeat surgery would worsen the patient's general con-
dition; therefore, we decided to perform BPA with digital subtrac-
tion angiography using meglumine gadopentetate (Magnevist;
Schering, Berlin, Germany).
The procedure involved placing a sheath (Arrow-Flex; Teleﬂex,
Durham, NC) in the vein and using a 0.035-inch guidewire (Radi-
focus Guide Wire M; Terumo, Tokyo, Japan) to insert a 6-french-
gauge (Fr) wedge-pressure catheter to the bifurcation of the pul-
monary trunk. Then, this was replaced with a 6-Fr long sheath
(Bright Tip sheath introducer; Cordis/Johnson & Johnson, New
Brunswick, NJ) before placing the catheter in the target pulmonary
artery. A 6-Fr multipurpose catheter (Mach 1 peripheral MP; Boston
Scientiﬁc, Natick, MA) was inserted through this and placed in the
pulmonary artery trunk. A 0.014-inch wire (Cruise; Asahi Intecc,
Tokyo, Japan) was then used to cross the lesion site andwas inﬂated
to 6e12 atm using a balloon catheter (2e4 mm, IKAZUCHI PAD,
Kaneka, Osaka, Japan). Digital subtraction angiography images
were acquired at a rate of 7.5 frames/s with settings of 78 Kv and
41 mAs.
The vessel branches that were dilated in each session were as
follows: in session 1, the posterior basal segmental artery of the
right lung (Rt.A10a, 10c); in session 2, the lateral basal segmental
artery of the left lung (Lt.A9b) and the posterior basal segmental
artery of the right lung (Lt.A10b); in session 3, the lateral basal
segmental artery of the right lung (Rt.A9b); in session 4, the ante-
rior basal segmental artery of the right lung (Rt.A8); and in session
5, the anterior basal segmental artery of the left lung (Lt.A8). Fig. 6
shows contrast-enhanced images from before and after additional
treatment on the right lower lobe branch. The ﬁve sessions were
concluded without any allergic reactions or complications.
The follow-up right heart catheterization at 4 months indicated
improvement to mild pulmonary hypertension with an mPAP of
28 mmHg and a pulmonary vascular resistance of 2.5 Wood units.
The pulmonary capillary wedge pressure was 4 mmHg, right atrial
pressure 1 mmHg, and cardiac index 3.9 L/min/m2, indicating
increased cardiac output. Improved right cardiac function was
shown by the right ventricular ejection fraction increasing from11%
Fig. 2. 12-Lead Electrocardiogram. Electrocardiogram showing right axis deviation, a pulmonary P wave in leads II, III, and aVF, and a negative T wave in leads III, aVF, and V1e4.
Fig. 3. Echocardiography. The left and right images show the short-axis and four-chamber views, respectively. Enlargement of the right atrium and ventricle and marked left-
ventricular displacement, are observed.
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the partial pressure of oxygen (pO2) was 66 Torr; in room air, the
pO2 was 110 Torr. Furthermore, exercise tolerance markedly
improved with the improved oxygenation and cardiac index: the
patient could walk 560 m in 6 min, and his maximal oxygenconsumption was 26.4 mL/min/kg during cardiopulmonary exer-
cise testing, despite previously being bedridden. His subjective
symptoms also improved from WHO stage IV to I and his body
weight decreased to 53 kg from 60.5 kg in the most exacerbated
stage.
Table 2
Clinical coarse.
pre PEA post PEA Hospitalization Exacerbation BPA 1st BPA 2nd BPA 3rd BPA 4th BPA 5th 4 month 15 month
WHO-FC Ⅲ Ⅰ Ⅲ Ⅳ Ⅲ Ⅲ Ⅲ Ⅲ Ⅱ Ⅰ Ⅰ
O2 (L)/DOB(g) room air/0 room air/0 room air/0 5.0/2.0 5.0/2.0 5.0/2.0 4.0/0 4.0/0 4.0/0 room air/0 room air/0
BP (mmHg) 109/73 127/81 118/75 105/72 110/68 120/68 120/68 122/68 127/69 124/76 105/70
HR (bpm) 86 101 88 106 120 112 102 95 98 98 88
BNP (pg/ml) 67 18 100 196 96 92 87 18 28 6 14
TRPG (mmHg) 58 24 95 120 100 97 60 42 47 30 22
RAP (mmHg) 0 0 2 9 6 3 3 7 1 1 1
PA (mPAP) (mmHg) 96/40 (56) 30/14 (20) 96/37 (57) 110/37 (67) 108/40 (65) 104/38 (63) 79/32 (49) 82/35 (48) 56/24 (35) 45/20 (28) 34/13 (20)
PCW (mmHg) 10 2 6 6 12 6 6 12 4 12 6
PVR (wood.units) 11.3 3.8 12.3 11.5 9 11 7.8 5.9 5.3 2.5 2.5
SvO2 (%) 69 70 67 58 76 74 78 79 83 72 75
CO/CI (L/m, L/m/m2) 4.1/2.3 4.8/2.9 4.2/2.4 5.3/3.1 5.8/3.4 5.6/3.4 6.7/4.0 6.6/4.0 7.9/4.8 6.5/3.9 5.9/3.5
MRI: RVEF (%) 11 23 31
MRI: LVEF (%) 40 46 50
pO2 (torr) 58 80 80 66 88 88 124 85 117 110 85
pCO2 (torr) 30 37 37 36 37 40 33 39 37 40 39
DLCO (%) 69 45 64 56 57 57 60 55 60 64
VC (%) 104 77 100 82 86 90 93 96 98 100
FEV1.0 (%) 78 99 82 82 83 80 84 82 83 87
peak VO2 (ml/min/kg) 26.4
AT (ml/min/kg) 7.8
6MWD (m) 260 370 560 570
Amount of Gd (ml) 90 50 59 40 45
WHO FC:World Health Organization Function Class, O2: Oxygen, DOB: Dobutamine Hydrochloride, BP: Blood Pressure, HR: Heart Rate, TRPG: Tricuspid Regurgitation Pressure
Gradient, mPAP: mean Pulomonary Artery Pressure, PCW: Pulmonary Capillary Wedge Pressure, PVR: Pulmonary Vascular Resistance, SvO2: Venous Oxygen Saturation ,CO:
Cardiac Output, CI: Cardiac Index, MRI:Magnetic Resonance Imaging, RVEF: Right Ventricular Ejection Fraction, LVEF: Left Ventricular Ejection Fraction, pO2: Partial Pressure of
Oxygen, pCO2: Partial Pressure of Carbon Dioxide, DLCO: Diffuse Capacity of Carbon Monoxide, FEV1.0: Forced Expiratory Volume % one second, Peak VO2: Peak Oxygen
Uptake, AT: Anaerobic Threshold, 6MWD: Six Minutes Walk Distance, Gd: Gadolinium contrast medium.
T. Nakamura et al. / Respiratory Medicine Case Reports 17 (2016) 75e8278At the 15-month follow-up examination, the patient had no
further exacerbations and remained at WHO stage I. Moreover, his
mPAP had improved to 20 mmHg, the pulmonary vascular resis-
tance had remained at 2.5 Wood units, and his right ventricularFig. 4. Pulmonary Angiography. The left and right images show the right and left pulmona
rowing, and disruption but no centrally operable lesion.ejection fraction had improved to 31%. Table 2 and Fig. 7 show the
changes in clinical data. The changes observed in chest X-ray im-
ages,12-lead electrocardiograms, echocardiograms, and ventilation
scintigraphy in Figs. 8e11 are consistent with pulmonaryry arteries, respectively. Pulmonary arteriography shows webbing, bands, abrupt nar-
Fig. 5. Lung Scintigraphy. The left and right images are of ventilation and perfusion scans, respectively. The perfusion imaging shows multiple segmental blood ﬂow decreases; the
ventilation imaging shows a ventilationeperfusion mismatch, with no ﬁlling defect.
Fig. 6. Balloon Pulmonary Angioplasty. The right and left images are pre-BPA and post-BPA, respectively. Contrast-enhanced images from before and after additional treatment
showing the lateral basal segmental artery of right lung (Rt.A9b). On DSA images, many peripheral vessels are seen post-BPA. Abbreviations: BPA, balloon pulmonary angioplasty;
DSA, digital subtraction angiography.
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Fig. 7. Clinical Course. This ﬁgure shows changes in the pulmonary arterial pressure with TRPG measured on cardiac echocardiography as an index. After PEA, the TRPG dropped to
24 mmHg but it later reached 95 mmHg during an exacerbation. After hospitalization, gradual exacerbation was observed despite the use of targeted medical therapy, and TRPG
eventually reached 120 mmHg. After that, TRPG decreased with each BPA procedure. After ﬁve BPA procedures, TRPG decreased to 30 mmHg at 4 months and 22 mmHg at 15
months. Abbreviations: Apr, April; BPA, balloon pulmonary angioplasty; Dec, December; Jan, January; PEA, pulmonary endarterectomy; TRPG, tricuspid regurgitation pressure
gradient; Nov, November; Oct, October.
Fig. 8. Changes over Time in Chest X-ray Film. Left image is post-PEA, center image is during an exacerbation after hospitalization, and right image is 15 months after BPA. During
exacerbation, enlargement of the second and fourth aortic arches is seen together with blood congestion, but these improved after BPA. Abbreviations: BPA, balloon pulmonary
angioplasty; PEA, pulmonary endarterectomy.
T. Nakamura et al. / Respiratory Medicine Case Reports 17 (2016) 75e8280hypertension pressure dynamics. The patient is being followed-up
on an outpatient basis and has reported no problems in his daily
life.
3. Discussion
PEA for central CTEPH is a safe and effective procedure with a
reported ﬁve-year survival rate of 82%, 10-year survival rate of 75%,
and perioperative mortality rate of 4.4% [5]. However, pulmonary
hypertension remains postoperatively in 10%e15% of patients, and
prognosis is generally poor in such cases [6,7]. In the present case,
although pulmonary hypertension improved after PEA, the lesionperipherally persisted. We believe that the thromboembolism then
progressed because of the underlying antiphospholipid antibody
syndrome, resulting in the later acute exacerbation. Furthermore,
because his symptoms rapidly worsened soon after hospitalization
and because therapy was ineffective for the pulmonary arterial
hypertension, there was a high risk of early mortality without
treatment.
Panitan et al. reported that allergies to iodine contrast media
occurred in 579 (1.05%) of 55,286 patients receiving the media. Of
these, 16 patients (0.03%) experienced serious symptoms and one
(0.002%) died. Thus, while the incidence is low, serious symptoms
can sometimes occur. In this case, the patient exhibited serious
Fig. 9. Changes over Time in 12-Lead Electrocardiograms. Left image is post-PEA, center image is during an exacerbation after hospitalization, and right image is 15 months after
BPA. During exacerbation, right axis deviation can be seen with descending type decreased ST and a negative T waves in the precordial leads. However, these improved after BPA.
Abbreviations: BPA, balloon pulmonary angioplasty; PEA, pulmonary endarterectomy.
Fig. 10. Changes over Time in Echocardiography. Left image is post-PEA, center image is during an exacerbation after hospitalization, and right image is 15 months after BPA. The D-
shape showing left-ventricular displacement disappeared after BPA. Abbreviations: BPA, balloon pulmonary angioplasty; PEA, pulmonary endarterectomy.
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iodine contrast medium and despite the use of premedication [8].
Recently, it has been reported that BPA is effective for inoperable
cases of peripheral CTEPH. In addition, gadolinium can be used for
patients who are allergic to iodine contrast media; however, there
have been no previous reports of cases inwhich BPAwas performed
using gadolinium in a patient with CTEPH. We report our experi-
ences of performing ﬁve sessions of BPA on a young patient whowe
considered would have had a poor prognosis without treatment.
The surgery was successfully concluded without complication, and
the patient's condition sufﬁciently improved for him to return to
his normal activities of daily living.
Meglumine gadopentetate is a gadolinium formulation towhich
meglumine and diethylenetriaminepentaacetic acid (DTPA) are
added as a pH adjuster and stabilizer, respectively. For each
contrast, 10 mL of meglumine gadopentetate at a dilution of
0.5 mmol/mL was used.
The beneﬁt of using gadolinium contrast medium is that it can
also be used on patients with severe iodine allergies. Problems
associated with gadolinium are its low viscosity, the fact that the
high speed of pulmonary arterial blood ﬂow makes it difﬁcult to
view the blood ﬂow with ﬂuoroscopy, and that the technique is
more difﬁcult thanwhen performedwith iodine contrast. The effectof gadolinium contrast has also been reported to be approximately
one ﬁfth that of an iodine contrast [9]; however, when an increased
amount of gadolinium contrast medium is used, it can cause renal
dysfunction. However, according to the guidelines for the use of
gadolinium contrast for patients with renal failure, as recom-
mended by the Japan Radiological Society and the Japan Society of
Nephrology, there is insufﬁcient evidence to support the claim that
renal function of GFR 60 mL/min/1.73 m2 increases the risk of
nephrogenic systemic ﬁbrosis (NSF). In the present case, GFR was
73.7 mL/min/1.73 m2. Therefore, during treatment, symptoms such
as itching sensation in skin, swelling, hardening and joint stiffness
were frequently checked and renal function was periodically
monitored through blood tests to conﬁrm that renal function had
not deteriorated. Importantly, gadolinium contrast medium is also
expensive, and because it is usually exclusively used with magnetic
resonance imaging, it is not covered by health insurancewhen used
for BPA. However, in this case, as the surgeon became familiar with
the procedure over repeated sessions and as the vessels were more
accurately targeted by advance examination and detailed planning,
the amount of gadolinium contrastmedium usedwas reduced from
90 mL to 40 mL, as shown in Table 2. We believe that this amount
could be further reduced with the use of optical coherence to-
mography [10].
Fig. 11. Changes over Time in Lung Scintigraphy Perfusion Imaging. Left image is pre-BPA and right image is 4 months after BPA. This ﬁgure shows changes in lung scintigraphy from
after PEA to during exacerbation, and at 4 months after BPA. The blood ﬂow in treated regions improved. Abbreviations: BPA, balloon pulmonary angioplasty; PEA, pulmonary
endarterectomy.
T. Nakamura et al. / Respiratory Medicine Case Reports 17 (2016) 75e8282We conclude that BPA using gadolinium may become an option
for severe CTEPH in patients who are allergic to iodine.
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